You are here: Industry Insights > Market News > China approves clinical trials for 16 indigenous COVID-19 vaccines

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

China approves clinical trials for 16 indigenous COVID-19 vaccines

expresspharmaFebruary 22, 2021

Tag: COVID-19 vaccine , china , Clinical Trial

Favorites

China has approved clinical trials for 16 indigenous COVID-19 vaccines, of which six are in the third stage, according to a state-run media report.

The latest vaccines for clinical trials are based on recombinant protein, adenovirus vector, nucleic acid and attenuated influenza-viruses technologies, state-run Xinhua news agency reported, citing data from the National Medical Products Administration.

China has already given conditional approval to two inactivated COVID-19 vaccines made by state-owned developers — Sinopharm and Sinovac Biotech.

As of February 9, China has given 40.52 million COVID-19 jabs to key groups, Xinhua reported, quoting a National Health Commission official.

Previous:Atlas Antibodies acquires HistoCyte Laboratories, a global leader in cell line controls for histopathology

Next:Serum Institute of India says prioritising domestic vaccine needs

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

China approves clinical trials for 16 indigenous COVID-19 vaccines | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Hot selling top quality health products Echinacea extract Chicoric Acid

Chinaroot Greenbrier Extract

High quality Triacetylganciclovir supplier in China High quality Triacetylganciclovir supplier in Ch

2-Amino-8-methoxy-chinazolin

K type Glass-Lined Chemical Reactor and tank with Good Price From China Manufacturer and Factory

China Factory supplier 99% purity KH 550 3-Amipropyltriethoxysilane CAS 919-30-2 in stock with free

Factory supply Echinacea Extract

Echinacea purpurea 4% Polyphenols supplier API Plant extract Pharmaceutical made in china

Desmopressin supplier API Pharmaceutical Polypeptide Urinary system drugs made in china

high quality and purity Veterinary drug Tylosin tartrate China

China approves clinical trials for 16 indigenous COVID-19 vaccines

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>